Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Bannwarth

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Expert Opinion on Investigational Drugs|May 11, 2005
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitorBernard Bannwarth, Francis Berenbaum
Nature Clinical Practice. Rheumatology|August 26, 2006
Peptic ulcer disease in a patient with ankylosing spondylitis receiving a conventional nonsteroidal anti-inflammatory drugBernard Bannwarth, Frank Zerbib
Drugs|February 5, 2004
[Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues]Bernard Bannwarth, Fabienne Péhourcq
Joint Bone Spine|July 17, 2009
The dextropropoxyphene controversyBernard Bannwarth, Christophe Richez
Expert Opinion on Pharmacotherapy|July 31, 2007
Lumiracoxib in the management of osteoarthritis and acute painBernard Bannwarth, Francis Bérenbaum
Drugs|June 30, 2017
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?Bernard Bannwarth, Marie Kostine
Drugs|April 3, 2014
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Bernard Bannwarth, Marie Kostine
Rheumatology (Oxford, England)|September 5, 2015
Comment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled studyBernard Bannwarth, Thomas Barnetche
The Journal of Rheumatology|February 14, 2003
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxibBernard Bannwarth, Philippe Ravaud, Maxine Dougados
Journal of Pharmaceutical and Biomedical Analysis|September 16, 2003
Potential of immobilized artificial membrane chromatography for lipophilicity determination of arylpropionic acid non-steroidal anti-inflammatory drugsFabienne Pehourcq, Christian Jarry, Bernard Bannwarth
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Expert Opinion on Investigational Drugs|May 11, 2005
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitorBernard Bannwarth, Francis Berenbaum
Nature Clinical Practice. Rheumatology|August 26, 2006
Peptic ulcer disease in a patient with ankylosing spondylitis receiving a conventional nonsteroidal anti-inflammatory drugBernard Bannwarth, Frank Zerbib
Drugs|February 5, 2004
[Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues]Bernard Bannwarth, Fabienne Péhourcq
Joint Bone Spine|July 17, 2009
The dextropropoxyphene controversyBernard Bannwarth, Christophe Richez
Expert Opinion on Pharmacotherapy|July 31, 2007
Lumiracoxib in the management of osteoarthritis and acute painBernard Bannwarth, Francis Bérenbaum
Drugs|June 30, 2017
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?Bernard Bannwarth, Marie Kostine
Drugs|April 3, 2014
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Bernard Bannwarth, Marie Kostine
Rheumatology (Oxford, England)|September 5, 2015
Comment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled studyBernard Bannwarth, Thomas Barnetche
The Journal of Rheumatology|February 14, 2003
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxibBernard Bannwarth, Philippe Ravaud, Maxine Dougados
Journal of Pharmaceutical and Biomedical Analysis|September 16, 2003
Potential of immobilized artificial membrane chromatography for lipophilicity determination of arylpropionic acid non-steroidal anti-inflammatory drugsFabienne Pehourcq, Christian Jarry, Bernard Bannwarth
Pageof 6